---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000183"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-09-05T23:59:59+00:00"
generated_at: "2026-05-17T07:54:59.479915+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions awarded $30M BARDA contract modification for CYFENDUS anthrax vaccine

## Summary
- Modification No. 20 valued at $30M for additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted).
- Deliveries begin calendar 2025 and are scheduled to be completed by March 2026.
- Follows a prior $50M modification in December 2024 for the same vaccine.
- CYFENDUS received FDA approval in July 2023 as a two-dose post-exposure prophylaxis for adults 18-65.

## SEC filing metadata
- accession: 0001367644-25-000183
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-09-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/0001367644-25-000183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000183/ebs-20250902.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000183
- JSON: https://secwatch.observer/filing/0001367644-25-000183.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.